Zai Lab (ZLAB) vs. Its Competitors Head to Head Comparison

Zai Lab (NASDAQ:ZLAB) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its competitors? We will compare Zai Lab to related companies based on the strength of its profitability, analyst recommendations, dividends, earnings, valuation, institutional ownership and risk.

Risk & Volatility

Zai Lab has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500. Comparatively, Zai Lab’s competitors have a beta of 1.16, indicating that their average stock price is 16% more volatile than the S&P 500.

Institutional and Insider Ownership

41.6% of Zai Lab shares are owned by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are owned by institutional investors. 4.9% of Zai Lab shares are owned by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Zai Lab and its competitors gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Zai Lab	$460.16 million	-$175.54 million	-14.77
Zai Lab Competitors	$698.13 million	$10.43 million	-15.37

Zai Lab’s competitors have higher revenue and earnings than Zai Lab. Zai Lab is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Zai Lab and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zai Lab	-41.86%	-27.43%	-16.72%
Zai Lab Competitors	-12,359.35%	-203.09%	-30.93%

Analyst Ratings

This is a summary of recent ratings for Zai Lab and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zai Lab	1	1	4	1	2.71
Zai Lab Competitors	9858	15137	45528	1590	2.54

Zai Lab currently has a consensus target price of $37.25, indicating a potential upside of 40.94%. As a group, “Biotechnology” companies have a potential upside of 99.44%. Given Zai Lab’s competitors higher possible upside, analysts plainly believe Zai Lab has less favorable growth aspects than its competitors.

Summary

Zai Lab competitors beat Zai Lab on 7 of the 13 factors compared.

About Zai Lab

Zai Lab is a biopharmaceutical company that discovers, develops and commercializes medicines for patients with serious diseases. Its research and development programs focus on oncology, immunology, neuroscience and infectious diseases. Founded in 2014 by biopharmaceutical executive Samantha Du, the company is headquartered in Shanghai and operates in China and the United States. It advances its own drug candidates and works with international partners to develop and bring therapies to market. Zai Lab’s portfolio includes medicines and development programs for cancers and other conditions, including therapies introduced through licensing and collaboration agreements.